Related Experiment Video

Updated: May 8, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

The Yin and Yang of Toll-like receptors in cancer

J-P Pradere1, D H Dapito2, R F Schwabe2

  • 1Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY, USA.

Oncogene
|August 13, 2013
PubMed

Insights

Toll-like receptors (TLRs) play a dual role in cancer, initiating anti-tumor immunity but also promoting tumor growth. Understanding these Toll-like receptor pathways is crucial for developing effective cancer therapies.

Area of Science:

  • Immunology
  • Oncology

Background:

  • Pattern recognition receptors, including Toll-like receptors (TLRs), are vital for innate immunity.
  • TLRs recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), influencing immune responses.
  • TLRs are implicated in both anti-tumor immunity and tumor-promoting inflammation during carcinogenesis.

Purpose of the Study:

  • To review the dichotomous role of Toll-like receptors (TLRs) in tumor biology.
  • To focus on TLR-dependent pro- and anti-tumor pathways.
  • To discuss clinical applications of TLR-targeted therapies for cancer prevention and treatment.

Main Methods:

  • Literature review of TLR function in cancer biology.
  • Analysis of TLR-dependent pro- and anti-tumorigenic signaling pathways.
  • Examination of clinical studies involving TLR agonists in cancer therapy.

Main Results:

  • TLRs can induce anti-tumor mediators like type I interferon via antigen-presenting cells.
  • TLRs are also recognized as regulators of tumor-promoting inflammation and survival signals.
  • The dual role of TLRs presents challenges and opportunities for cancer treatment.

Conclusions:

  • TLRs exhibit a complex, context-dependent role in cancer, acting as both promoters and inhibitors of tumor progression.
  • Targeting TLRs offers potential therapeutic strategies for cancer prevention and treatment.
  • Further research into specific TLR pathways is needed to optimize clinical applications.

More Related Videos

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis07:45

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis

Published on: January 26, 2024

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.